Guardian Pharmacy Services (GRDN) Stock Price, News & Analysis

Company Overview

Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company's Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs. The company was founded in 2003 and is based in Atlanta, Georgia.

Key Stats

• Today's Range: $20.96 to $21.57
• 50-Day Range: $19.65 to $26.44
• 52-Week Range: $14.16 to $26.91
• Volume: 985,760 shs
• Average Volume: 182,011 shs
• Market Capitalization: $1.35 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.67
• Consensus Rating: Buy

Guardian Pharmacy Services Stock Analysis - MarketRank™

Guardian Pharmacy Services scored higher than 23% of companies evaluated by MarketBeat, and ranked 851st out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.5 / 5
• Analyst Rating: Buy

Consensus Rating

Guardian Pharmacy Services has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Guardian Pharmacy Services has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: -3.45%

Earnings Growth

Earnings for Guardian Pharmacy Services are expected to decrease by -3.45% in the coming year, from $0.87 to $0.84 per share.

Price to Book Value per Share Ratio

Guardian Pharmacy Services has a P/B Ratio of 9.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for GRDN.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Guardian Pharmacy Services does not currently pay a dividend.

Dividend Growth

Guardian Pharmacy Services does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for GRDN.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: N/A

News Sentiment

Guardian Pharmacy Services has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Guardian Pharmacy Services this week, compared to 3 articles on an average week.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Guardian Pharmacy Services insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $228,713,426.00 in company stock.

Percentage Held by Insiders

63.71% of the stock of Guardian Pharmacy Services is held by insiders. A high percentage of insider ownership can be a sign of company health.

GRDN Stock Analysis - Frequently Asked Questions

How have GRDN shares performed this year?

Guardian Pharmacy Services' stock was trading at $20.26 at the beginning of 2025. Since then, GRDN stock has increased by 5.6% and is now trading at $21.3960.
View the best growth stocks for 2025 here.

How were Guardian Pharmacy Services' earnings last quarter?

Guardian Pharmacy Services, Inc. (NYSE:GRDN) announced its earnings results on Monday, May, 12th. The company reported $0.21 EPS for the quarter, missing analysts' consensus estimates of $0.22 by $0.01. The business had revenue of $329.31 million for the quarter, compared to the consensus estimate of $321.21 million.
Read the conference call transcript.

When did Guardian Pharmacy Services IPO?

Guardian Pharmacy Services (GRDN) raised $102 million in an IPO on Thursday, September 26th 2024. The company issued 6,800,000 shares at $14.00-$16.00 per share. Raymond James, Stifel and Truist Securities served as the underwriters for the IPO.

Who are Guardian Pharmacy Services' major shareholders?

Guardian Pharmacy Services' top institutional shareholders include Brown Advisory Inc. (2.53%), Wellington Management Group LLP (0.73%), Woodline Partners LP (0.67%) and Driehaus Capital Management LLC (0.64%). Insiders that own company stock include William E Bindley, Thomas J Salentine Jr, Fred Burke, David K Morris, Kendall Forbes, John Ackerman and Steven D Cosler.
View institutional ownership trends.

How do I buy shares of Guardian Pharmacy Services?

Shares of GRDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Guardian Pharmacy Services own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Guardian Pharmacy Services investors own include UnitedHealth Group (UNH) and Meta Platforms (META).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 6/29/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Retail
• Current Symbol: NYSE:GRDN
• Previous Symbol: NYSE:GRDN
• CIK: 1802255
• Web: guardianpharmacy.com
• Phone: (404) 810-0089
• Fax: N/A
• Employees: 3,400
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $25.67
• High Stock Price Target: $28.00
• Low Stock Price Target: $21.00
• Potential Upside/Downside: +20.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.14
• Quick Ratio: 0.84

Sales & Book Value

• Annual Sales: $1.23 billion
• Price / Sales: 1.10
• Cash Flow: $0.25 per share
• Price / Cash Flow: 85.71
• Book Value: $2.37 per share
• Price / Book: 9.03

Miscellaneous

• Outstanding Shares: 63,290,000
• Free Float: 22,967,000
• Market Cap: $1.35 billion
• Optionable: N/A
• Beta: N/A